Good month. 40 papers. I think the main takeaway here is the buprenorphine waiver required for U.S. providers to treat their patients with buprenorphine – it needs to go. It is an archaic and absurd construct essentially invented by the US Supreme Court a century ago when the court decided “addiction is not a disease”.Read More
PubMed Update June 2019
Oo – this was a good month! Wish I had seen these papers when they came out – 40 great articles addressing lots of medical management of overdose, as well as overdose prevention programs. Thanks again to Rebecca Martinez, Cathleen Beliveau, Nataliya Karashchuk, and Laila Esfandiari at the Center on Substance Use and Health (www.csuhsf.org)Read More
PubMed Update March 2019
43 new papers for March of 2019. 1) Fighting fire with fire: development of intranasal nalmefene to treat synthetic opioid overdose. Krieter P, Gyaw S, Crystal R, Skolnick P. J Pharmacol Exp Ther. 2019 Apr 2. pii: jpet.118.256115. doi: 10.1124/jpet.118.256115. [Epub ahead of print] Comments: Nalmefene has high affinity and >7h duration of effect. But not atRead More
PubMed Update January 2019
We start out 2019 with 42 new papers. The overarching theme is fentanyl – with some useful data really starting to emerge. Also several addressing surveillance-type issues, which is still badly needed and exciting work. We’ve also got the standard naloxone papers and a few weird drugs (e.g. tramadol and kratom). 1) Drugs Most Frequently InvolvedRead More